Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration

FDA Did Not Identify Any Clinical Safety or Efficacy Deficiencies and Did Not Request Additional Clinical Data

Company Advancing a Dual-Source Manufacturing Strategy, Adding a U.S.-Based Site, Toward NDA Resubmission